Skip to main content
Premium Trial:

Request an Annual Quote

Kyowa Selects Second Cancer Drug Candidate under Dicerna Partnership


Dicerna Pharmaceuticals this week announced that partner Kyowa Hakko Kirin has decided to advance a second cancer drug candidate into formal development as part of the companies' ongoing alliance.

The move has triggered a $5 million milestone payment to Dicerna.

The firms began working together in 2010 as part of a deal that gave Kyowa access to Dicerna's Dicer-substrate RNAi technology against cancer targets (GSN 1/7/2010). In 2011, Kyowa chose to develop the first drug candidate worked on under the arrangement and began exploring a second (GSN 12/5/2011). The companies also expanded the partnership to include immunologic and inflammatory diseases.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.